Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12284857 | 0.74 | USP2 (0.31) | — | |
| SCHEMBL4016388 | 0.70 | — | — | |
| SCHEMBL995245 | 0.67 | MEN1 (0.39) | MEN1KMT2AMAPT | |
| SCHEMBL4163468 | 0.64 | — | — | |
| SCHEMBL7570930 | 0.62 | MEN1 (0.35) | MEN1KMT2AMAPT | |
| SCHEMBL28351607 | 0.61 | CA2 (0.37) | — | |
| SCHEMBL4840036 | 0.59 | CA2 (0.35) | — | |
| SCHEMBL28210389 | 0.59 | CA2 (0.35) | — | |
| Methylene Chloride SCHEMBL18529805 | 0.58 | — | — | |
| SCHEMBL7737717 | 0.57 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114716548-B | Anti-FGFR 3 antibodies and uses thereof | (株)爱恩德生物 | 2024-11-05 | — | — | CN | claimed |
| US-20240002419-A1 | RADIATION-ACTIVATED TETRAVALENT PLATINUM COMPLEX AND USE THEREOF | PEKING UNIVERSITY (CN) | 2024-01-04 | — | — | US | claimed |
| CN-110312533-B | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | 拜耳公司 | 2023-11-03 | — | — | CN | claimed |
| CN-116981693-A | anti-FGFR 3 antibodies and uses thereof | (株)爱恩德生物 | 2023-10-31 | — | — | CN | claimed |
| EP-4253391-A1 | RADIATION-ACTIVATED TETRAVALENT PLATINUM COMPLEX AND USE THEREOF | Peking University (CN) | 2023-10-04 | — | — | EP | claimed |
| CN-116782937-A | anti-PD-1 antibodies and uses thereof | 优特力克斯有限公司 | 2023-09-19 | — | — | CN | claimed |
| CN-114716548-A | anti-FGFR 3 antibodies and uses thereof | (株)爱恩德生物 | 2022-07-08 | — | — | CN | claimed |
| EP-3558386-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | Bayer Aktiengesellschaft (DE) | 2019-10-30 | — | — | EP | claimed |
| WO-2018114798-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | BAYER AKTIENGESELLSCHAFT (DE) | 2018-06-28 | — | — | WO | claimed |
| US-7705045-B2 | compounds comprising a specifier linked to two or more of the same or different leaving groups via a self-eliminating multiple release spacer or spacer system, which compounds upon a single activation step, in particular removal or transformation of the specifier, release two or more leaving groups | SYNTARGA, B.V. (NL) | 2010-04-27 | — | — | US | claimed |
| EP-1370298-B1 | ELONGATED AND MULTIPLE SPACERS IN ACTIVATIBLE PRODRUGS | SYNTARGA BV (NL) | 2008-10-08 | — | — | EP | claimed |
| US-7223837-B2 | Anticancer prodrugs, enhance enzymatic activation rates | SYNTARGA B.V. (NL) | 2007-05-29 | — | — | US | claimed |
| US-20060116422-A1 | Prodrugs built as multiple self-elimination-release spacers | SYNTARGA B.V. (NL) | 2006-06-01 | — | — | US | claimed |
| EP-1560599-A1 | PRODRUGS BUILT AS MULTIPLE SELF-ELIMINATION-RELEASE SPACERS | Syntarga B.V. (NL) | 2005-08-10 | — | — | EP | claimed |
| CN-1511044-A | Elogated and multiple spacers in activatible prodrugs | — | 2004-07-07 | — | — | CN | claimed |
| US-20040121940-A1 | Elongated and multiple spacers in activatible produgs | BYONDIS B.V. (NL) | 2004-06-24 | — | — | US | claimed |
| WO-2004043493-A1 | PRODRUGS BUILT AS MULTIPLE SELF-ELIMINATION-RELEASE SPACERS | SYNTARGA B.V. (NL) | 2004-05-27 | — | — | WO | claimed |
| EP-1243276-A1 | Elongated and multiple spacers containing activatible prodrugs | De Groot, Franciscus Marinus Hendrikus (NL) | 2002-09-25 | — | — | EP | claimed |
| EP-0624377-B1 | Lysosomal enzyme-cleavable antitumor drug conjugates | BRISTOL MYERS SQUIBB CO (US) | 2002-01-23 | — | — | EP | claimed |
| EP-0624377-A2 | Lysosomal enzyme-cleavable antitumor drug conjugates | Bristol-Myers Squibb Company (US) | 1994-11-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116422-A1 | Prodrugs built as multiple self-elimination-release spacers | DNPEP, GUSB, APEH | MEN1 308/4885KMT2A 2365/4885MAPT 4176/4885 |
| US-20040121940-A1 | Elongated and multiple spacers in activatible produgs | PLG, KLK1, PKM | MEN1 168/4885KMT2A 774/4885MAPT 4372/4885 |
| US-20240002419-A1 | RADIATION-ACTIVATED TETRAVALENT PLATINUM COMPLEX AND USE THEREOF | XPA, F2, CXCR3 | MEN1 108/4885KMT2A 4280/4885MAPT 4170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.